Allergan, the manufacturers of BIOCELL textured “gummy” breast implants, is the target of a proposed national class-action lawsuit by consumer-rights law firm FeganScott. The suit claims that although the FDA issued a recall for Allergan’s BIOCELL products, the company has no plans to provide medical monitoring for individuals at risk of developing breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
According to the suit, filed in U.S. District Court for the Southern District of Iowa, Central Division, Allergan refuses to appropriately care for, monitor and compensate individuals who seek to remove the recalled implants or undergo invasive and expensive diagnostic procedures.
“For decades, Allergan knew that its recalled implants were six times more likely to cause BIA-ALCL, but it continued to market these products, seemingly with little regard for the well-being of its users.”
Read the full article here.